Loading news...
Investors need to pay close attention to ATR stock based on the movements in the options market lately.
AptarGroup, Inc. (ATR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission M eeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026 Results of the pivotal STAR-T study for DrugSorb ® -ATR have recently been accepted for publication in a top cardiac surgery journal Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces 2026 Quarterly Conference Call Dates.
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Present at 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Copeland Capital Management LLC acquired a new position in shares of AptarGroup, Inc. (NYSE: ATR) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 125,733 shares of the industrial products company's stock, valued at approximately $16,806,000.
Congress Asset Management Co. lowered its position in AptarGroup, Inc. (NYSE: ATR) by 99.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,674 shares of the industrial products company's stock after selling 510,857 shares during the quarter. Congress Asset Management Co.'s
AptarGroup, Inc. (NYSE: ATR - Get Free Report) has been assigned an average recommendation of "Hold" from the eight research firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have given a buy recommendation to the
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that its Bidose (BDS) Liquid Nasal Spray System is the mechanism for delivering the newly approved CARDAMYST™ (etripamil) Nasal Spray. CARDAMYST received approval by the U.S. Food and Drug Administration (FDA) for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhyt.
CW Advisors LLC lowered its position in shares of AptarGroup, Inc. (NYSE: ATR) by 21.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,118 shares of the industrial products company's stock after selling 15,848 shares during the quarter. CW Advisors
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Named One of America's Most Responsible Companies by Newsweek for the Seventh Consecutive Year.
Edgestream Partners L.P. purchased a new position in AptarGroup, Inc. (NYSE: ATR) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 21,754 shares of the industrial products company's stock, valued at approximately $3,403,000. Several other institutional investors also recently bought
Investors need to pay close attention to ATR stock based on the movements in the options market lately.
On Monday, AptarGroup, Inc. (NYSE: ATR) acquired Sommaplast, a specialized provider of oral dosing pharma packaging solutions, such as closures, droppers, dispensers, and dosing cups, based in Brazil.
Creative Planning increased its holdings in AptarGroup, Inc. (NYSE: ATR) by 55.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,277 shares of the industrial products company's stock after purchasing an additional 2,233 shares during the period. Creative Planning's
Boston Family Office LLC lessened its holdings in AptarGroup, Inc. (NYSE: ATR) by 2.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 163,138 shares of the industrial products company's stock after selling 3,390 shares during the period. AptarGroup
AXQ Capital LP acquired a new position in shares of AptarGroup, Inc. (NYSE: ATR) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,667 shares of the industrial products company's stock, valued at approximately $261,000. Several other institutional investors have also
Aviso Financial Inc. boosted its holdings in AptarGroup, Inc. (NYSE: ATR) by 24.6% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 17,755 shares of the industrial products company's stock after buying an additional 3,508 shares during the quarter. Aviso Financial Inc.'s
The Touchstone Mid Cap Fund (Class A Shares, Load Waived) underperformed its benchmark, the Russell MidCap® Index, for the quarter ended September 30, 2025. Among the largest contributors to Fund performance were Somnigroup International, Inc. (Consumer Discretionary sector), Armstrong World Industries, Inc. (Industrials sector), and NewMarket Corporation (Materials sector). Among the largest detractors from Fund performance were Fidelity National Information Services, Inc. (Financials sector), Allison Transmission Holdings, Inc. (Industrials sector), and AptarGroup, Inc. (Materials sector).
AptarGroup, Inc. ( ATR ) Jefferies London Healthcare Conference 2025 November 19, 2025 7:00 AM EST Company Participants Stephan Tanda - President, CEO & Executive Director Gael Touya - President of Aptar Pharma Vanessa Kanu - Executive VP & CFO Conference Call Participants Daniel Rizzo - Jefferies LLC, Research Division Presentation Daniel Rizzo Jefferies LLC, Research Division Good afternoon. I am Dan Rizzo with Jefferies Equity Research.